Quantcast
Last updated on April 18, 2014 at 7:23 EDT

Latest Immunosuppressants Stories

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-02-06 16:27:04

Unsealed federal lawsuit alleges that pharmaceutical giant engaged in unlawful marketing schemes involving blockbuster drugs Thalomid and Revlimid in cancer treatment, costing taxpayers hundreds of millions of dollars; charges of kickbacks to physicians in pushing for unapproved treatments LOS ANGELES and WASHINGTON, Feb. 6, 2014 /PRNewswire/ -- Leading whistleblower law firm Grant & Eisenhofer P.A. represents a key whistleblower in a false claims lawsuit unsealed today against...

2014-02-05 20:23:53

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/9lglrg/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" [http://www.researchandmarkets.com/research/9lglrg/biologics_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics...

2014-01-27 12:29:27

Potential U.S. Commercialization Targeted for 2014 CHICAGO, Jan. 27, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid...

2014-01-22 12:26:41

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class InnovationFrontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation SummaryGBI Research has released a new pharmaceutical report, "Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation". This highly competitive market...

2014-01-13 12:28:03

LONDON, Jan. 13, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Next Generation Stent Technologies (Technical Insights) Milestones in stent technologies achieved through proper funding sources This research service (RS) is a study on the funding prospects in the stent market. Stents are one of the most breakthrough medical devices in the cardiology market. The RS delivers content on the prevalent investor climate in this industry, and attempts to...

2014-01-08 12:30:01

HORSHOLM, Denmark, Jan. 8, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus(®). The subject patent covers a method of administering Envarsus(®), Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose(®)...

2013-12-30 04:20:18

HORSHOLM, Denmark, Dec. 30, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus(®) (formerly LCP-Tacro(TM)) for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and...

2013-12-25 23:01:37

ResearchMoz.us include new market research report " Global and China Monoclonal Antibody Industry Report, 2013 - 2017 " to its huge collection of research reports. Browse full report - http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html Albany, NY (PRWEB) December 25, 2013 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the...